The Trade Desk rockets to $1 billion after IPO
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
The Trade Desk prices shares at $18 and IPO raises $84 million
Shares of Ventura-based digital marketing firm The Trade Desk priced at $18 per share Sept. 20, at the high end of its price range. As of 9:30 a.m. PST, shares of The Trade Desk’s Class A common stock were trading at $29.17. By pricing at the high end of its price range, The Trade Desk Read More →
The Trade Desk increases share price range for IPO
Ventura-based digital marketing firm The Trade Desk increased the price range it expects to sell its shares for when the company holds its initial public offering. In documents filed with the Securities and Exchange Commission Sept. 22, The Trade Desk increased its pricing point to between $16 and $18 per share and expects to sell Read More →
QAD announces quarterly dividend
QAD announced a quarterly dividend of 7.2 cents per share for Class A common stock and 6 cents per share for Class B common stock on Sept. 15. QAD has declared the same dividend for 13 of the past 14 quarters. Headed by QAD President and Chairman Pamela Lopker and her husband and CEO Karl Read More →
Resonant plans to raise $9.2 million in public offering
Resonant, a late stage Goleta development company designing small smartphone technology, plans to raise $9.2 million in a public offering. Documents filed with the Securities and Exchange Commission Sept. 9 said the company plans to offer about 2.4 million shares for $4.25 per share. The company expects to complete the offering by Sept. 14. Resonant Read More →
Greed drives skyrocketing cost of drugs in the U.S.
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
FDA approves Amgen’s Blincyto
The U.S. Food and Drug Administration approved Amgen’s drug Blincyto for treating pediatric leukemia patients Sept. 1. In Dec. 2014, the FDA approved Blincyto to treat patients with precursor B-cell acute lymphoblastic leukemia, which is a rare form of the disease. On Sept. 1, the agency extended Blincyto’s approval to include pediatric patients with another Read More →
